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Greece. The study was carried out in 2006 and participants were
face-to-face interviewed to report on their use of pharmaceuticals
and on the number of pharmaceuticals taken in a speciﬁed recent
period. Multivariable logistic regression analysis was performed
to ascertain the predictive factors of the pharmaceutical con-
sumption. Statistical signiﬁcance was accepted at the 5% level.
RESULTS: A total of 43.7% of the sample had used pharmaceu-
ticals. Age, chronic diseases, HRQoL, number of physician
consultations and hospitalization were best predictors of phar-
maceutical use. Factors associated with higher likelihood of using
pharmaceuticals were elderly people (exp(b) = 1.72, CI:1.51–
1.70), chronic diseases (exp(b) = 6.61, CI:3.39–9.96), poorer
HRQOL (PSC12 exp(b) = 0.93, CI:0.90–0.95, MCS12
exp(b) = 0.97, CI:0.93–0.99) and number of physician consulta-
tions during the last year (exp(b) = 3.05, CI:1.96–4.76). On the
other hand, taking four or more pharmaceuticals concurrently
were best predicted by older age (exp(b) = 1.52, CI:1.11–2.09),
chronic diseases (exp(b) = 3.84, CI: 1.58–5.94), poorer HRQOL
(PCS12 exp(b) = 0.95, CI:0.92–0.97, MCS12 exp(b) = 0.95, CI:
0.93–0.98), number of physician consultations during the year
(exp(b) = 3.59, CI: 1.36–5.41) and hospitalization during the last
year (exp(b) = 2.13, CI:1.13–4.02). CONCLUSIONS: Pharma-
ceutical use is related to population aging (combined with
chronic disease) a fact that should be a cause of concern in the
future, taking into account the demographic problem in the
western societies.
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OBJECTIVES: The aim of this research was to analyze outhospi-
tal drug consumption in Montenegro in 2007, and to compare
data with drug consumption in previous period. The aim was also
to compare drug consumption in Montenegro with drug con-
sumption in countries with developed prarmacotherapeutic prac-
tice. METHODS: Drug consumption was analyzed by number of
DDD per 1000 inhabitants per day. Consumption of ﬁnancial
resources was analyzed as well. RESULTS: Total outhospital drug
consumption funded by Republic Health Fund of Montenegro in
2007. was 278.59 DDD/1000 inhabit./day. The highest consump-
tion was in group C (drugs for cardiovascular diseases) with
149.29 DDD/1000 inhabit./day (53.59% of total drug consump-
tion). Second highest consumption was in group A (drugs for
alimentary tract andmetabolism)with 34.67 DDD/1000 inhabit./
day (12.45% of total drug consumption). Drugs for nervous
system participated with 10.50% in total drug consumption with
29.25 DDD/1000 inhabit./day. Total drug consumption funded
by Republic Health Fund of Montenegro in 2007. was increased
for 36.68% compared to drug consumption in 2005.
(203.82 DDD/1000 inhabit./day). Increase in drug consumption
resulted in increased consumption of ﬁnancial resources
(12.859.961.58 €) which were higher for 2.857.855.73 € then in
2005. Highest increase in consumption of ﬁnancial resources was
in group C (€1,096.468.28 in 2007.), group A (€559,827.80
in 2007.), group R (€468,156.55 in 2007.) and group N
(€452,212.30 in 2007.). CONCLUSIONS: Although there was a
signiﬁcant decrease in drug consumption in Montenegro in 2007.
compared to 2005. drug consumption in 2007. was much lower
then in Scandinavian countries. Detailed analysis in separate ATC
groups of drugs reveal that consumption is not always rational
from pharmacoterapeutic and pharmacoeconomic point of view.
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OBJECTIVES: To identify most frequently used and most inﬂu-
ential sources of information on drugs in Poland, as well as to
determine their credibility as perceived by GPs’ and possible
factors limiting access to these sources. METHODS: An anony-
mous survey was conducted among one hundred GPs in ambu-
latories in Warsaw, Poland. GPs were questioned about the
sources of information used in the past six months and frequency
of usage. GPs were also asked to divide 100 pts to indicate the
most important limitations in access to sources, the perceived
credibility of the sources and the sources inﬂuencing the decision
most. Demographic questions were included. RESULTS:
[UNKNOWN NODETYPE 9] Only 25% GPs considered them-
selves limited in the access to drug information, while 69%
believed the information was sufﬁcient. The most frequent bar-
riers referred to GPs themselves: lack of foreign language skills
(average of 24.7 points); money limitations (22.4), lack of time
(20.87 pts), no EBM competency (20.6). There is a statistically
signiﬁcant (all tests for a = 0.05) negative relation between usage
and perceived limitations. Younger GPs perceived lack of infor-
mation statistically signiﬁcantly more often (Fisher’s exact test).
The sources that were most frequently used in the past 6 months
were: drug directories (96% GPs), pharmaceutical companies
representatives (93%), polish professional journals (92.6%).
High importance of commercial sources conﬁrmed previous
results of POLKARD-SPOK survey in Poland and agrees with
results of surveys in other countries. On the other hand the SPOK
survey showed higher role of Polish professional journals. GPs
declared that drug selection is inﬂuenced most by medical jour-
nals (29.16 pts), medical books (24.93), and information from
pharmaceutical companies representatives (21.15). There is a
slight discrepancy between usage and inﬂuence, which may
suggest an element of wishful thinking. CONCLUSIONS: Rela-
tively few GPs feel insufﬁciently informed. Whether this is an
objective (i.e. results from their proﬁciency) or subjective fact (i.e.
results from their lack of knowledge of information gap) should
be a matter of further studies. Information gained from pharma-
ceutical companies representatives is an important factor both in
terms of frequency and impact on decisions. Confronting this
with limitations of GPs in gathering new information by them-
selves proves there is a need for EBM popularization in Poland.
PHP18
COMPARISON OF COST/QALY RATIO IN DIAGNOSTIC AND
THERAPEUTIC DEVICES OR DRUGS
Rodríguez Bezos D, Serrano D, Rodríguez Barrios JM
Medtronic Iberica, Madrid, Madrid, Spain
OBJECTIVE: In the last years, economic evaluations with
quality adjusted life year (QALY) as effectiveness variable
increased. Cost-utility analyses are generally preferred by health
care policy makers and payers, because include both quality and
quantity of life. Also, QALY allows comparing different inter-
ventions with the same evaluation unit. The majority of eco-
nomic studies evaluate drugs, despite of increment of diagnostic
and therapeutic devices studies in the last years. The main objec-
tive consists on a comparison of Cost/QALY ratio in diagnostic
and therapeutic devices with drug treatments in studies devel-
oped in the Spanish setting in the last 12 years. METHOD: A
Spanish cost-effectiveness and cost-utility studies review was
developed, including all published studies during the last 12
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years. The data bases used were PubMed/MEDLINE and
EMBASE. Also, Spanish magazines not indexed in MEDLINE
were reviewed. A review about growth of cost-utility published
studies and other about threshold of the health technology in
Spain, both were included too. Abstracts of Medtronic therapies
and other health technology and devices enterprises were
reviewed. Costs were in euros of the year 2007. RESULTS:
Thirty-one studies with cost/QALY ratio were identiﬁed, 22 of
drug therapies and 8 of diagnostic and therapeutic devices. Cost/
QALY ratio of drug therapies oscillated between -€25.937
(Dasatinib in patients resistant to imatimab in myeloid leukemia)
and €72,583 (Pneumococcal vaccine vs. no vaccine in patients
5–24 years). In diagnostic and therapeutic devices cost/QALY
ratio was between -€30,664 (DES vs. BMS) and €34.389 (Sub-
thalamus stimulation vs. conventional medical therapy in
advanced Parkinson). CONCLUSIONS: In the reviewed studies,
diagnostic and therapeutic devices were cost-effective with a cost
per QALY relation under or near the efﬁciency threshold usually
accepted in Spain. This relation in some cases was lower than
drug therapies used in the usual clinical practice.
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OBJECTIVES: To determine if there are regional market access
inequalities for innovative antineoplastic and immunomodula-
tory drugs (AID) in Spain. METHODS: All new AIDs introduced
in Spain were identiﬁed between 2002 and 2007. AID units
adjusted by population and region were analyzed by means of the
IMS Health Databases: EMF, EMH, and EMHEMF. The time
horizon considered was 12 months prior to September 2007
(MAT 09/07). Regions were the minimal geographic unit allowed
by the databases in order to ensure the representativeness of the
data (I: Aragon, Catalonia, Balearic Islands; II: Valencia, Murcia;
III: Andalusia, Canary Islands; IV: Castile la Mancha, Extrema-
dura, Madrid; V: Asturias, Castile-Leon, Galicia, Navarra,
Basque Country, La Rioja, Cantabria). RESULTS: In Spain,
between January 2002 and October 2007, 16 AIDs were
approved. For methodological limitations only ten drugs were
analyzed: three hospital diagnostic (HD) (imatinib, erlotinib y
sorafenib), six hospital use (H) (alemtuzumab, bortezomib, beva-
cizumab, cetuximab, ibritumomab and pemetrexed) and 1
medical prescription (fulvestrant). HD drugs showed high vari-
ability in units per in-habitant between regions. Erlotinib pre-
sented a 27.7% Standard Deviation (SD) between zones,
concentrating the 69% in zone I. The 31% was distributed
uniformly in the other regions. Imatinib presented a 25% SD,
zone I and V covered the 53.6% and 40.3% of the units
respectively. Sorafenil presented less geographic variation
(SD = 10.1%). Regional differences between hospital drugs were
smaller. SD oscillated between 9.8% (bevacizumab) and 5.3%
(pemetrexed). Zone II presented the highest market share. When
analysing fulvestrant, zones I and V concentrated the 60.9% of
the units and the inter-regional SD was 13.6%. CONCLU-
SIONS: There are important regional inequalities in the number
of units per in-habitant sold for new AIDs. Zones I and V
presented the highest market share whereas in the other zones
market access is highly restricted.
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OBJECTIVES: On the February 15, 2007 new forms of
co-payment were introduced in Hungary: visit fee (300 HUF/
visit) in the outpatient care and hospital daily fee (300 HUF/day)
in the inpatient care. The aim of this study is to analyze the effect
of the introduction of hospital daily fee on the number of inpa-
tient admissions to acute care hospital wards in Hungary
METHODS: The data derive from the ﬁnancial database of the
National Health Insurance Fund Administration (OEP) of
Hungary covering the period of 2006–2008. We analyzed the
number of admissions during a 10 months period before (from
March 2006 to January 2007) and after (from March 2007 to
January 2008) the introduction of daily fee. Data from February
2007 were omitted. RESULTS: During the 10 months period
before the introduction of hospital daily fee the total number of
admissions was 2,285,011, while during the 10 months period
after the introduction of daily fee it decreased to 1.940.880. The
average monthly number of admissions was 207,728 before and
176,444 after the introduction of daily fee. This represents a
15.1% decrease in the number of acute care admissions. CON-
CLUSIONS: The introduction of hospital daily fee in the Hun-
garian inpatient care resulted in a signiﬁcant decrease of acute
inpatient care admissions. However we do not have information
whether admissions failed to be realized were really unnecessary
or not. Other elements of the health care reforms could have also
inﬂuenced the number of admissions.
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OBJECTIVES: On the 15th of February 2007 new forms of
co-payment were introduced in Hungary: visit fee (300 HUF/
visit) in the outpatient care and hospital daily fee (300 HUF/day)
in the inpatient care. The aim of this study is to analyze the effect
of the introduction of visit fee on the number of patient-visits to
outpatient care departments in Hungary. METHODS: The data
derive from the ﬁnancial database of the National Health Insur-
ance Fund Administration (OEP) of Hungary covering the period
of 2006–2008. We analyzed the number of patient visits during
a 10 months period before (from March 2006 to January 2007)
and after (from March 2007 to January 2008) the introduction
of visit fee. Data from February 2007 were omitted. RESULTS:
During the 10 months period before the introduction of visit fee
the total number of visits was 64,309,067, while during the 10
months period after the introduction of visit fee it decreased to
51.927.150. The average monthly number of outpatient visits
was 5,846,279 before and 4,720,650 after the introduction of
visit fee. This represents a 19.3% decrease in the number of
outpatient visits. CONCLUSIONS: The introduction of visit fee
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